Jonathan Alspaugh serves as Executive at Aeglea BioTherapeutics, Inc., where they oversee executive responsibilities. Since joining the company, Jonathan Alspaugh has executed 5 insider transactions totaling $604.7K, demonstrating a bullish approach to their equity position. Their most recent transaction on Mar 11, 2022 involved purchasing 75,000 shares valued at $156.0K.
Jonathan Alspaugh currently holds 165,372 shares of Aeglea BioTherapeutics, Inc. (AGLE), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Jonathan Alspaugh has been a net buyer of AGLE stock. They have purchased $604.7K and sold $0 worth of shares.
Jonathan Alspaugh's most recent insider trade was on Mar 11, 2022, when they purchased 75,000 shares at $2.08 per share.
Get notified when new Form 4 filings are submitted
| $3.72 |
| Discretionary |
| Aug 18, 2021 | AGLE | $48.4K | Purchase | 7,200 | $6.72 | Discretionary |
| Aug 17, 2021 | AGLE | $152.0K | Purchase | 23,392 | $6.50 | Discretionary |
| Aug 16, 2021 | AGLE | $62.3K | Purchase | 9,780 | $6.37 | Discretionary |